The estimated Net Worth of Virland A Johnson is at least $458 Tisíc dollars as of 25 March 2020. Mr Johnson owns over 13,486 units of JanOne stock worth over $85,886 and over the last 6 years he sold JAN stock worth over $250,185. In addition, he makes $121,731 as Chief Financial Officer at JanOne.
Mr has made over 5 trades of the JanOne stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 32,933 units of JAN stock worth $220,651 on 24 May 2021.
The largest trade he's ever made was selling 32,933 units of JanOne stock on 24 May 2021 worth over $220,651. On average, Mr trades about 15,203 units every 143 days since 2018. As of 25 March 2020 he still owns at least 38,514 units of JanOne stock.
You can see the complete history of Mr Johnson stock trades at the bottom of the page.
Virland A. Johnson CPA is the Chief Financial Officer at JanOne.
As the Chief Financial Officer of JanOne, the total compensation of Mr CPA at JanOne is $121,731. There are 1 executives at JanOne getting paid more, with Tony Isaac having the highest compensation of $534,471.
Mr CPA is 61, he's been the Chief Financial Officer of JanOne since . There are 1 older and no younger executives at JanOne. The oldest executive at JanOne Inc. is Tony Isaac, 67, who is the Pres, CEO, Corp. Sec. & Director.
Virland's mailing address filed with the SEC is 325 E Warm Springs Rd #102, Las Vegas, NV 89119, USA.
Over the last 5 years, insiders at JanOne have traded over $250,185 worth of JanOne stock. The most active insiders traders include Virland A Johnson a Antonios Isaac. On average, JanOne executives and independent directors trade stock every 213 days with the average trade being worth of $51,758. The most recent stock trade was executed by Virland A Johnson on 24 May 2021, trading 32,933 units of JAN stock currently worth $220,651.
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.
JanOne executives and other stock owners filed with the SEC include: